Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer. - Kalkner, K. M.; Acosta, S.; Thorsson, O.; Frederiksen, H.; Nilsson, A.; Gustavsson, B.; Elingsbo, M.; Stridsberg, M.; Abrahamsson, P-A. (Prostate Cancer & Prostatic Diseases, 2006)